Springboard Enterprises Announces 2022 Life Sciences Innovation Program
Ten Women-Led Life Sciences Companies to Begin Virtual Bootcamp March 17
WASHINGTON, DC: MARCH 16, 2022 – Continuing its mission of accelerating the growth of entrepreneurial companies founded and led by women, Springboard Enterprises has announced its 2022 Life Sciences Innovation Cohort. During the next three months, entrepreneurs and founders from ten women-led Life Sciences companies will participate in an intensive entrepreneurial bootcamp, a wide-ranging workshop series, and ultimately be matched with a team of strategic advisors to educate and support them as they navigate their next stage of growth.
The ten companies selected for the Life Sciences Innovation Program represent a multitude of innovative solutions to address acute real-world needs in healthcare, disease management, and digital technology. The 2022 cohort participants include:
BioNADRx is an early clinical-stage biotech company focused on developing novel therapeutic formulations (Portfolio in a Product) based on the coenzyme Nicotinamide Adenine Dinucleotide (NAD+) for prescription and non-prescription indications.
BRT Biotechnologies, Inc. is finding lifesaving and life-changing small molecule therapeutics
Cellfe Biotech transforms the way gene therapies are manufactured to enable affordable advanced treatments for all. The company uses a microfluidics-based transfection platform that can be adapted universally to enable low-cost, high-yield manufacturing of cell therapies at scale.
CxPrecision Medicine (CxPM) is changing expectations for patients suffering from neurodegenerative diseases by developing tools to accelerate diagnosis, facilitate personalized therapeutic treatment and improve patient outcomes.
Eisana is developing novel, affordable, tech-enabled products to prevent and treat devastating side effects from cancer treatment.
Ernest Pharma is engineering bacteria to safely treat solid tumors
NasaClip is a safe, effective, low-cost solution for nosebleed rescue that will be the “Band-Aid” of nosebleeds for children and adults.
Obatala Sciences is a revenue-generating bioTools company that is revolutionizing drug development within the fields of obesity, diabetes, and regenerative medicine by manufacturing the first-to-market human tissue models of diverse patient populations for drug screening.
Paradox Immunotherapeutics develops immunotherapies to combat protein misfolding diseases using a proven-successful antibody design platform; their specialized antibodies selectively target and remove disease-causing forms of proteins that cause organ dysfunction.
Relavo is changing the way that kidney failure patients receive treatment by making home dialysis safer and more accessible.
For details on how to participate in future cohorts, please contact Springboard Director of Programs, Emily Harris, at emily@springboardenterprises.org.
About Springboard Enterprises
Springboard's mission is to accelerate the growth of entrepreneurial companies led by women through access to essential resources and a global community of experts. We are a leading network of influencers, investors, and innovators dedicated to building companies at scale led by women who are transforming industries in technology and life science. The measure of our success is in the results. Since 2000, over 850 Springboard portfolio companies seeking investment and human capital for product development and expansion have created over $36.4B in value. With 225 exits to strategic acquirers and 26 IPOs, Springboard Entrepreneurs are transforming industries. Learn more: springboardenterprises.org
If you are looking for our Life Sciences 2021 cohort, please click here.